Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Brown Fat Can Be Beneficial For The Body – And a Blood Pressure Drug Could Turn It On : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-18

Short answerEvidenceSource

Short answer

Not supported

Not supported.

One claim goes further than the study. 4 other points were not covered by the paper.

  • 1 overstated
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

One claim overstates the study. Four claims the study doesn't address.

  • 1 overstated
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedA new study in Nature from researchers led by a team at Rockefeller University presents more evidence that brown fat may boost not just physical health, but mental health too.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an association between BAT presence/activity and more favorable cardiometabolic/cardiovascular and psychiatric disease patterns. However, the lead phrasing that brown fat may 'boost' physical and mental health uses causal/benefit language that outruns the observational human evidence, especially for psychiatric outcomes. The paper profile does not establish that BAT improves mental health; it reports lower prevalence of psychiatric diseases among people with BAT.

1

Study evidence

Across a cohort of 101,243 patients, cardiovascular and psychiatric diseases were reported as less prevalent in people with detectable brown adipose tissue (BAT).

“Here we leveraged big data and artificial intelligence to systematically define the clinical impact of BAT in a cohort of 101,243 patients from a large cancer centre.”
2

Study evidence

Higher BAT activity was associated with lower odds of cardiometabolic diseases.

“Using a machine learning approach, we semi-automatically quantified BAT activity in approximately 8,700 patients”
Claim 2 of 5Not coveredThe blood pressure drug losartan was associated with a greater likelihood of having detectable brown fat in the human study data.View evidenceHide evidence

Why this verdict

The abstract-level profile says angiotensin receptor blocker use was positively associated with BAT presence. It does not verify that losartan specifically, rather than the ARB class, was associated with a greater likelihood of detectable BAT in the human data, nor does it provide effect size or adjustment details.

1

Study evidence

Angiotensin receptor blocker (ARB) use was positively associated with presence of brown adipose tissue (BAT).

“Analysis of medication usage demonstrated that angiotensin receptor blocker use was positively associated with BAT presence.”
Claim 3 of 5Not coveredThe researchers found that people with detectable brown fat were significantly less likely to have type 2 diabetes or heart disease, and also less likely to have anxiety or depression.View evidenceHide evidence

Why this verdict

The abstract supports the broad direction that cardiovascular and psychiatric diseases were less prevalent in people with detectable BAT, and that higher BAT activity was associated with lower odds of cardiometabolic diseases. But at abstract depth the profile does not verify the specific diagnoses listed in the story—type 2 diabetes, heart disease, anxiety, and depression—or the stated statistical significance for those specific comparisons.

1

Study evidence

Across a cohort of 101,243 patients, cardiovascular and psychiatric diseases were reported as less prevalent in people with detectable brown adipose tissue (BAT).

“Here we leveraged big data and artificial intelligence to systematically define the clinical impact of BAT in a cohort of 101,243 patients from a large cancer centre.”
2

Study evidence

Higher BAT activity was associated with lower odds of cardiometabolic diseases.

“Using a machine learning approach, we semi-automatically quantified BAT activity in approximately 8,700 patients”
Claim 4 of 5Not coveredIn mouse experiments, animals given losartan had brown fat that was more active, burning more energy and producing more heat, though the health benefits of that activation still need to be determined.View evidenceHide evidence

Why this verdict

The abstract supports a proof-of-concept experimental claim that losartan increased brown adipocyte activity and whole-body energy expenditure. But the abstract-level profile does not specify that the experiments were in mice, does not verify heat production specifically, and provides no experimental details or effect magnitudes. The caveat that health benefits remain to be determined is directionally consistent with the proof-of-concept framing but is not itself detailed in the abstract profile.

1

Study evidence

Losartan increased brown adipocyte activity and whole-body energy expenditure (reported as proof-of-concept).

“As proof of concept, we showed that the angiotensin receptor blocker losartan increased brown adipocyte activity and whole-body energy expenditure.”
Claim 5 of 5Not coveredThe article says the human association between blood pressure drugs and brown fat was identified in people, while the drug’s brown-fat-activating effect was demonstrated in mice, and the human database consisted of cancer patients, mostly women.View evidenceHide evidence

As stated101,243 study participants; nearly 8,900 with detectable brown fat; more than three-quarters women

Why this verdict

Several broad distinctions are supported: the medication association was observational human database evidence, losartan activation evidence was experimental proof of concept, and the cohort came from a large cancer centre with 101,243 patients. However, at abstract depth the profile does not verify that the losartan experiment was in mice, that the database consisted entirely of cancer patients, that more than three-quarters were women, or that nearly 8,900 people had detectable BAT. The profile instead mentions approximately 8,700 patients in a machine-learning BAT-activity subset.

1

Study evidence

Across a cohort of 101,243 patients, cardiovascular and psychiatric diseases were reported as less prevalent in people with detectable brown adipose tissue (BAT).

“Here we leveraged big data and artificial intelligence to systematically define the clinical impact of BAT in a cohort of 101,243 patients from a large cancer centre.”
2

Study evidence

Angiotensin receptor blocker (ARB) use was positively associated with presence of brown adipose tissue (BAT).

“Analysis of medication usage demonstrated that angiotensin receptor blocker use was positively associated with BAT presence.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Machine-learning semi-automated BAT activity quantification was performed in approximately 8,700 patients, with higher BAT activity—especially axillary BAT—associated with lower cardiometabolic disease odds and healthier white fat distribution.

    The story does not clearly reflect the ML-based BAT activity quantification contribution, the axillary-depot emphasis, or the white-fat-distribution finding. It appears to convert the ~8,700 imaging/activity subset into a count of people with detectable BAT, which is not what the abstract-level profile states.

    From ML-enabled secondary-data phenotyping

  • People with BAT had more favorable glycaemic parameters, lipid profiles, inflammatory markers, and echocardiographic indices.

    The story discusses broad physical-health associations, diabetes, heart disease, and brown-fat activation, but it does not report the paper’s biomarker and echocardiography findings as a distinct material element.

    From retrospective secondary data analysis

  • Medication association is vulnerable to confounding by indication, exposure-timing uncertainty, and medication-exposure misclassification.

    The story distinguishes human association from experimental evidence, but it does not mention the medication-analysis-specific limitations identified in the profile.

    From retrospective observational medication-association analysis

7 things the story did carry across
  • Very large retrospective human cohort: 101,243 patients from a large cancer centre used to compare disease prevalence by detectable BAT presence.
  • BAT presence was associated with lower prevalence of cardiovascular and psychiatric diseases across diagnoses.
  • Medication-usage analysis found angiotensin receptor blocker use positively associated with BAT presence.
  • Proof-of-concept experimental evidence reported that losartan increased brown adipocyte activity and whole-body energy expenditure.
  • Human cohort findings are retrospective and observational, so they do not establish cause and effect.
  • Cancer-centre cohort and selection/generalizability limitations affect interpretation.
  • The losartan proof-of-concept experiment is not sufficient, at abstract depth, to show clinical benefit or human BAT activation; experimental system, sample sizes, methods, and effect magnitudes are not specified in the abstract profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataDefine the clinical impact of brown adipose tissue (BAT) presence across diagnoses using a very large patient cohort (big-data phenotyping).Retrospective cohort phenome-wide association (EHR-based) studyExpand

In plain English

Retrospective, EHR-based phenome-wide association analysis in 101,243 patients from a large cancer centre found that people with detectable brown adipose tissue (BAT) had lower prevalence of several diagnoses, with cardiovascular and psychiatric diseases highlighted as less common in the BAT-positive group. The study used big-data approaches and artificial intelligence to perform an unbiased scan across diagnoses.

Key findings

  • Across a cohort of 101,243 patients, cardiovascular and psychiatric diseases were reported as less prevalent in people with detectable brown adipose tissue (BAT).
  • The analyses were conducted in a very large cohort (101,243 patients) using big-data and artificial intelligence methods to perform an unbiased phenome-wide assessment of clinical conditions associated with BAT presence.
“Here we leveraged big data and artificial intelligence to systematically define the clinical impact of BAT in a cohort of 101,243 patients from a large cancer centre.”
What this piece can’t prove
  • Retrospective, observational design limits causal inference.
  • Study population drawn from a cancer centre; findings may not generalize to non-cancer or community populations.
  • Abstract lacks numerical effect estimates, model specifications, and details of covariate adjustment, hindering assessment of the magnitude and robustness of associations.
  • Potential for residual confounding and selection bias inherent to EHR-based analyses.
2secondary dataDevelop/use an AI/ML approach to semi-automatically quantify BAT activity from clinical imaging in a subset, and relate BAT activity (including depot-specific activity such as axillary) to cardiometabolic outcomes and fat distribution.ML-enabled secondary-data phenotypingExpand

In plain English

The study applied a machine-learning–enabled, semi-automated pipeline to quantify brown adipose tissue (BAT) activity from clinical imaging in ~8,700 patients and tested associations between continuous/semi-quantitative BAT activity (including depot-specific activity, notably axillary) and cardiometabolic disease odds and white fat distribution, finding that higher BAT activity—especially in the axillary depot—was associated with lower odds of cardiometabolic diseases and healthier white fat distribution.

Key findings

  • Higher BAT activity was associated with lower odds of cardiometabolic diseases.
  • BAT activity in the axillary depot showed especially strong association with lower cardiometabolic disease odds and healthier white fat distribution.
“Using a machine learning approach, we semi-automatically quantified BAT activity in approximately 8,700 patients”
What this piece can’t prove
  • Abstract does not report imaging modality, ML model type, training/validation approach, or performance metrics for the BAT activity quantification.
  • Unclear selection criteria and representativeness of the ~8,700-patient imaging subset relative to the larger cohort.
  • Observational design limits causal inference; potential for residual confounding and reverse causation.

2 further details could not be confirmed from the summary.

3secondary dataAssociate BAT presence/activity with detailed clinical biomarkers and physiologic readouts (glycaemia, lipids, inflammatory markers, echocardiographic indices).retrospective secondary data analysisExpand

In plain English

In a retrospective big-data cohort from a large cancer centre, presence (and higher activity) of brown adipose tissue (BAT) was associated cross-sectionally with more favourable glycaemic measures, lipid profiles, lower inflammatory markers, and more favourable echocardiographic indices.

Key findings

  • People with BAT exhibited more favourable glycaemic parameters, lipid profiles, inflammatory markers, and echocardiographic indices.
“People with BAT also exhibited more favourable glycaemic parameters, lipid profiles, inflammatory markers and echocardiographic indices.”
What this piece can’t prove
  • Unclear temporal relationship between BAT measurement and biomarker/echocardiography data; causality cannot be inferred.
  • Methods for extracting and harmonizing laboratory and echocardiography measures from clinical records are not described.
  • Subset used for BAT activity quantification (~8,700) may not represent the full cohort; representativeness for biomarker/echo analyses is unspecified.

2 further details could not be confirmed from the summary.

4secondary dataIdentify medications associated with BAT presence (with emphasis on angiotensin receptor blockers) to motivate drug-repurposing hypotheses.retrospective observational medication-association analysisExpand

In plain English

In an observational medication-usage analysis within a cohort drawn from a large cancer centre (n = 101,243), the authors report that angiotensin receptor blocker (ARB) use was positively associated with presence of brown adipose tissue (BAT). The paper also reports ML-based semi-automated quantification of BAT activity in ~8,700 patients used in related analyses, and presents losartan experiments (increasing brown adipocyte activity and whole-body energy expenditure) as a proof-of-concept for ARB repurposing to activate BAT.

Key findings

  • Angiotensin receptor blocker (ARB) use was positively associated with presence of brown adipose tissue (BAT).
“Analysis of medication usage demonstrated that angiotensin receptor blocker use was positively associated with BAT presence.”
What this piece can’t prove
  • Study population from a single large cancer centre may limit generalizability to broader populations.
  • The association reported is observational and does not on its own establish causality; experimental losartan results are presented separately as proof-of-concept.

2 further details could not be confirmed from the summary.

5otherProvide proof-of-concept experimental validation that the angiotensin receptor blocker losartan can increase brown adipocyte activity and whole-body energy expenditure.Expand

In plain English

The authors report a proof-of-concept experimental result that the angiotensin receptor blocker losartan increased brown adipocyte activity and whole-body energy expenditure. The abstract does not specify the experimental system, sample sizes, measurement methods, or effect magnitudes.

Key findings

  • Losartan increased brown adipocyte activity and whole-body energy expenditure (reported as proof-of-concept).
“As proof of concept, we showed that the angiotensin receptor blocker losartan increased brown adipocyte activity and whole-body energy expenditure.”
What this piece can’t prove
  • Unclear whether the intervention was performed in humans, animals, or in vitro, which affects applicability to clinical repurposing.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Vasomotor effects of noradrenaline, 5-hydroxytryptamine, angiotensin II, bradykinin, histamine, and acetylcholine on the bat (Rhinolophus ferrumequinum) basilar artery.

Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP · 2021 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.